Emerging Blood-Based Biomarkers for Predicting Immunotherapy Response in NSCLC

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2022 Jun 10

PMID 35681606

Authors

Ana Oitaben

Pablo Fonseca

Maria J Villanueva

Carme Garcia-Benito

Aida Lopez-Lopez

Alberto Garrido-Fernandez

Clara Gonzalez-Ojea

Laura Juaneda-Magdalena

Martin E Lazaro

Monica Martinez-Fernandez

Affiliations

Soon will be listed here.

Abstract

Immunotherapy with Immune Checkpoint Inhibitors (ICIs) has demonstrated a profitable performance for Non-Small Cell Lung Cancer (NSCLC) cancer treatment in some patients; however, there is still a percentage of patients in whom immunotherapy does not provide the desired results regarding beneficial outcomes. Therefore, obtaining predictive biomarkers for ICI response will improve the treatment management in clinical practice. In this sense, liquid biopsy appears as a promising method to obtain samples in a minimally invasive and non-biased way. In spite of its evident potential, the use of these circulating biomarkers is still very limited in the real clinical practice, mainly due to the huge heterogeneity among the techniques, the lack of consensus, and the limited number of patients included in these previous studies. In this work, we review the pros and cons of the different proposed biomarkers, such as soluble PD-L1, circulating non-coding RNA, circulating immune cells, peripheral blood cytokines, and ctDNA, obtained from liquid biopsy to predict response to ICI treatment at baseline and to monitor changes in tumor and tumor microenvironment during the course of the treatment in NSCLC patients.

Citing Articles

Biomarkers for immunotherapy resistance in non-small cell lung cancer.

Rother C, John T, Wong A Front Oncol. 2025; 14:1489977.

PMID: 39749035 PMC: 11693593. DOI: 10.3389/fonc.2024.1489977.

Blood biomarkers to predict the efficacy of neoadjuvant chemo-immunotherapy in non-small cell lung cancer patients.

Pan Y, Jin X, Hong J, Wang Y, Xu H, Lin J Transl Lung Cancer Res. 2024; 13(10):2773-2786.

PMID: 39507016 PMC: 11535834. DOI: 10.21037/tlcr-24-717.

Circulating Interleukins as Biomarkers in Non-Small Cell Lung Cancer Patients: A Pilot Study Compared to Normal Individuals.

Lim W, Leung J, Xie C, Cheng A, Su L, Lum L Diseases. 2024; 12(9).

PMID: 39329890 PMC: 11430979. DOI: 10.3390/diseases12090221.

MiRNAs and Microbiota in Non-Small Cell Lung Cancer (NSCLC): Implications in Pathogenesis and Potential Role in Predicting Response to ICI Treatment.

Nucera F, Ruggeri P, Claudia Spagnolo C, Santarpia M, Ieni A, Monaco F Int J Mol Sci. 2024; 25(12).

PMID: 38928392 PMC: 11203619. DOI: 10.3390/ijms25126685.

Pan-cancer analysis of super-enhancer-induced LINC00862 and validation as a SIRT1-promoting factor in cervical cancer and gastric cancer.

Liu S, Wang Z, Hu L, Ye C, Zhang X, Zhu Z Transl Oncol. 2024; 45:101982.

PMID: 38718436 PMC: 11097084. DOI: 10.1016/j.tranon.2024.101982.

References

Ando K, Hamada K, Watanabe M, Ohkuma R, Shida M, Onoue R . Plasma Levels of Soluble PD-L1 Correlate With Tumor Regression in Patients With Lung and Gastric Cancer Treated With Immune Checkpoint Inhibitors. Anticancer Res. 2019; 39(9):5195-5201. DOI: 10.21873/anticanres.13716. View

Zhang Y, Chang L, Yang Y, Fang W, Guan Y, Wu A . The correlations of tumor mutational burden among single-region tissue, multi-region tissues and blood in non-small cell lung cancer. J Immunother Cancer. 2019; 7(1):98. PMC: 6448263. DOI: 10.1186/s40425-019-0581-5. View

Dovizio M, Bruno A, Contursi A, Grande R, Patrignani P . Platelets and extracellular vesicles in cancer: diagnostic and therapeutic implications. Cancer Metastasis Rev. 2018; 37(2-3):455-467. DOI: 10.1007/s10555-018-9730-4. View

Zhu X, Lang J . Soluble PD-1 and PD-L1: predictive and prognostic significance in cancer. Oncotarget. 2017; 8(57):97671-97682. PMC: 5722594. DOI: 10.18632/oncotarget.18311. View

Costantini A, Julie C, Dumenil C, Helias-Rodzewicz Z, Tisserand J, Dumoulin J . Predictive role of plasmatic biomarkers in advanced non-small cell lung cancer treated by nivolumab. Oncoimmunology. 2018; 7(8):e1452581. PMC: 6136870. DOI: 10.1080/2162402X.2018.1452581. View

Norum J, Nieder C . Tobacco smoking and cessation and PD-L1 inhibitors in non-small cell lung cancer (NSCLC): a review of the literature. ESMO Open. 2018; 3(6):e000406. PMC: 6173248. DOI: 10.1136/esmoopen-2018-000406. View

Serrati S, Guida M, Di Fonte R, De Summa S, Strippoli S, Iacobazzi R . Circulating extracellular vesicles expressing PD1 and PD-L1 predict response and mediate resistance to checkpoint inhibitors immunotherapy in metastatic melanoma. Mol Cancer. 2022; 21(1):20. PMC: 8764806. DOI: 10.1186/s12943-021-01490-9. View

Oh S, Kim S, Keam B, Kim T, Kim D, Heo D . Soluble PD-L1 is a predictive and prognostic biomarker in advanced cancer patients who receive immune checkpoint blockade treatment. Sci Rep. 2021; 11(1):19712. PMC: 8492653. DOI: 10.1038/s41598-021-99311-y. View

Halvorsen A, Sandhu V, Sprauten M, Flote V, Kure E, Brustugun O . Circulating microRNAs associated with prolonged overall survival in lung cancer patients treated with nivolumab. Acta Oncol. 2018; 57(9):1225-1231. DOI: 10.1080/0284186X.2018.1465585. View

10.

Keegan A, Ricciuti B, Garden P, Cohen L, Nishihara R, Adeni A . Plasma IL-6 changes correlate to PD-1 inhibitor responses in NSCLC. J Immunother Cancer. 2020; 8(2). PMC: 7537334. DOI: 10.1136/jitc-2020-000678. View

11.

Ou C, Vu T, Grunwald J, Toledano M, Zimak J, Toosky M . An ultrasensitive test for profiling circulating tumor DNA using integrated comprehensive droplet digital detection. Lab Chip. 2019; 19(6):993-1005. PMC: 6559803. DOI: 10.1039/c8lc01399c. View

12.

Gong B, Kiyotani K, Sakata S, Nagano S, Kumehara S, Baba S . Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non-small cell lung cancer. J Exp Med. 2019; 216(4):982-1000. PMC: 6446862. DOI: 10.1084/jem.20180870. View

13.

Schabath M, Welsh E, Fulp W, Chen L, Teer J, Thompson Z . Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma. Oncogene. 2015; 35(24):3209-16. PMC: 4837098. DOI: 10.1038/onc.2015.375. View

14.

Skoulidis F, Goldberg M, Greenawalt D, Hellmann M, Awad M, Gainor J . Mutations and PD-1 Inhibitor Resistance in -Mutant Lung Adenocarcinoma. Cancer Discov. 2018; 8(7):822-835. PMC: 6030433. DOI: 10.1158/2159-8290.CD-18-0099. View

15.

Rizvi N, Hellmann M, Snyder A, Kvistborg P, Makarov V, Havel J . Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015; 348(6230):124-8. PMC: 4993154. DOI: 10.1126/science.aaa1348. View

16.

Palanca-Ballester C, Rodriguez-Casanova A, Torres S, Calabuig-Farinas S, Exposito F, Serrano D . Cancer Epigenetic Biomarkers in Liquid Biopsy for High Incidence Malignancies. Cancers (Basel). 2021; 13(12). PMC: 8233712. DOI: 10.3390/cancers13123016. View

17.

Johnson D, Nebhan C, Moslehi J, Balko J . Immune-checkpoint inhibitors: long-term implications of toxicity. Nat Rev Clin Oncol. 2022; 19(4):254-267. PMC: 8790946. DOI: 10.1038/s41571-022-00600-w. View

18.

Yin Z, Yu M, Ma T, Zhang C, Huang S, Karimzadeh M . Mechanisms underlying low-clinical responses to PD-1/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1. J Immunother Cancer. 2021; 9(1). PMC: 7818841. DOI: 10.1136/jitc-2020-001698. View

19.

Baiden-Amissah R, Tuyaerts S . Contribution of Aging, Obesity, and Microbiota on Tumor Immunotherapy Efficacy and Toxicity. Int J Mol Sci. 2019; 20(14). PMC: 6678743. DOI: 10.3390/ijms20143586. View

20.

Wang J, Zeng H, Zhang H, Han Y . The role of exosomal PD-L1 in tumor immunotherapy. Transl Oncol. 2021; 14(5):101047. PMC: 7921878. DOI: 10.1016/j.tranon.2021.101047. View